1. Wasserheit JN. The STD-HIV Connection from Research to Action: Are We Lost in Translation?; 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, California. 2007.
2. Padian NS. Biomedical HIV Prevention: Current Status, Challenges, and Future Directions. 4th Annual International AIDS Society; Syndney: 2007.
3. Wasserheit JN. STI/HIV Prevention Research: The Agony, The Ecstasy, & The Future. 18th International Society for Sexually Transmitted Disease Research; London: 2009.
4. Lay PD. AIDS remains an exceptional issue. BMJ Rapid Response. 2008
5. UNAIDS. Report on the Global AIDS Epidemic. Geneva: 2008.
6. Institute of Medicine (IOM) Methodological Challenges in Biomedical HIV Prevention Trials. Washington, D.C.: The National Academies Press; 2008.
7. Padian NS, Buve A, Balkus J, Serwadda D, Cates W., Jr Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372:585–599. [PubMed] 8. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: The importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5:8. [PMC free article] [PubMed] 9. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et al. Public health. Reassessing HIV prevention. Science. 2008;320:749–750. [PMC free article] [PubMed] 10. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, et al. Whither or wither microbicides? Science. 2008;321:532–534. [PMC free article] [PubMed] 11. Lagakos SW, Gable AR. Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med. 2008;358:1543–1545. [PubMed] 12. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet. 2000;355:1981–1987. [PubMed]
13. Higgins JPT, Green S, editors. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] 2008.
14. Kamb ML, Fishbein M, Douglas JM, Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161–1167. [PubMed] 15. Hobfoll SE, Jackson AP, Lavin J, Johnson RJ, Schroder KE. Effects and generalizability of communally oriented HIV-AIDS prevention versus general health promotion groups for single, inner-city women in urban clinics. J Consult Clin Psychol. 2002;70:950–960. [PubMed] 16. Branson BM, Peterman TA, Cannon RO, Ransom R, Zaidi AA. Group counseling to prevent sexually transmitted disease and HIV: a randomized controlled trial. Sex Transm Dis. 1998;25:553–560. [PubMed] 17. Baker SA, Beadnell B, Stoner S, Morrison DM, Gordon J, Collier C, et al. Skills training versus health education to prevent STDs/HIV in heterosexual women: a randomized controlled trial utilizing biological outcomes. AIDS Educ Prev. 2003;15:1–14. [PubMed]
18. Pequagnat W. Group NCHSPT. Results of the RCT to test the community popular opinion leader (C-POL) intervention in five countries. AIDS 2008 - XVII international AIDS Conference: Abstract no LBPE1166
19. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 2003;361:645–652. [PubMed]
20. Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, et al. Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial; 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada. 2009.
21. Rothman KJ, Greenland S. Modern Epidemiology. 2nd. Philadelphia: Lippincott Williams & Wilkins; 1998.
22. Cohen MS. Preventing sexual transmission of HIV. Clin Infect Dis. 2007;45(4):S287–292. [PubMed] 23. Vermund SH, Allen KL, Karim QA. HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS. 2009;4:266–273. [PMC free article] [PubMed] 24. Gray RH. Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings) Curr Opin HIV AIDS. 2009;4:274–278. [PMC free article] [PubMed]
25. Medical Research Council. Microbicide Gel Safe but Not Effective in Preventing HIV Infection. Press Release; Durban: Dec 14, 2009.
26. Cowan FM, Pascoe SJ, Langhaug LF, Dirawo J, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri Project: a cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe--study design and baseline results. Trop Med Int Health. 2008;13:1235–1244. [PubMed]
27. Cowan FM, Pascoe SJS, Langhaug LF, Dirawo J, Mavhu W, Chidiya S, et al. 18th International Society for Sexually Transmitted Disease Research. London: 2009. The Regai Dzive Shiri Project: Results of a Cluster Randomized Trial of a Multi-Component HIV Prevention Intervention for Rural Zimbabwean Adolescents.
28. Gray GE, Allen MA, Bekker L, Churchyard G, Mlisana K, Nchabeleng M, et al. AIDS Vaccine. Cape Town: 2008. Results from the Phambili (HVTN 503) Study: A Multicenter Phase IIB Test-of-concept Study of the MRKad5 HIV-1 Gag/Pol/Nef Vaccine in South Africa.
29. Celum C, Wald A, Lingappa J, Magaret A, Wang R, Mugu N, et al. Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1/HSV-2 co-infected persons within HIV-1 serodiscordant couples: a randomized, double-blind, placebo-controlled trial; 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; Cape Town, South Africa. 2009.
30. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364:41–50. [PubMed]
31. Patterson TL, Orozovich P, Semple SJ, Orozco HSS, Fraga M, Amaro H, et al. A Sexual Risk Reduction Intervention for Female Sex Workers in Mexico: Design and Baseline Characteristics. Journal of HIV/AIDS & Social Services. 2006;5:115–137.
32. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–2119. [PMC free article] [PubMed] 33. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654–665. [PubMed] 34. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. [PMC free article] [PubMed] 35. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472. [PubMed] 36. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971–977. [PubMed] 37. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. 2009 [PubMed] 38. Ross DA, Changalucha J, Obasi AI, Todd J, Plummer ML, Cleophas-Mazige B, et al. Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. AIDS. 2007;21:1943–1955. [PubMed] 39. Corbett EL, Makamure B, Cheung YB, Dauya E, Matambo R, Bandason T, et al. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS. 2007;21:483–489. [PubMed] 40. Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, Duvvury N. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ. 2008;337:a506. [PMC free article] [PubMed] 41. Pronyk PM, Hargreaves JR, Kim JC, Morison LA, Phetla G, Watts C, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet. 2006;368:1973–1983. [PubMed] 42. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530–536. [PubMed] 43. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999;353:525–535. [PubMed] 44. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med. 2007;4:e102. [PMC free article] [PubMed] 45. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet. 2009;374:229–237. [PMC free article] [PubMed] 46. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477–482. [PubMed] 47. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504–510. [PubMed] 48. Richardson BA, Lavreys L, Martin HL, Jr, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394–400. [PubMed] 49. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE. 2007;2:e1312. [PMC free article] [PubMed] 50. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE. 2008;3:e3784. [PMC free article] [PubMed] 51. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008;3:e1474. [PMC free article] [PubMed] 52. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2:e27. [PMC free article] [PubMed] 53. Ghys PD, Diallo MO, Ettiegne-Traore V, Satten GA, Anoma CK, Maurice C, et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS. 2001;15:1421–1431. [PubMed] 54. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA. 2004;291:2555–2562. [PubMed] 55. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560–1571. [PMC free article] [PubMed] 56. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370:251–261. [PMC free article] [PubMed] 57. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–1987. [PubMed] 58. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–666. [PubMed] 59. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–656. [PubMed] 60. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298. [PMC free article] [PubMed]
61. U.S. Military HIV Research Program. RV144 Phase III HIV Vaccine Trial Press Release. Rockville, MD: 2009.
62. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006;20:1471–1479. [PubMed] 63. Quigley MA, Kamali A, Kinsman J, Kamulegeya I, Nakiyingi Miiro J, Kiwuwa S, et al. The impact of attending a behavioural intervention on HIV incidence in Masaka, Uganda. AIDS (London, England) 2004;18:2055–2063. [PubMed] 64. Patterson TL, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ, Fraga-Vallejo M, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health. 2008;98:2051–2057. [PMC free article] [PubMed] 65. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009;23:461–469. [PMC free article] [PubMed] 66. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009 [PMC free article] [PubMed]
67. Gray G, Allen M, Churchyard G, Bekker L, Nchabeleng M, Mlisana K, et al. AIDS Vaccine. Paris: 2009. A multicenter double-blind randomized placebo-controlled Phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa.
68. Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on HIV vaccines. AIDS. 2009;23:3–8. [PMC free article] [PubMed]
69. Buchbinder S. AIDS Vaccine. Paris: 2009. Clinical Outcomes from the STEP Study.
70. UNAIDS. UNAIDS Case Study. Geneva: 2000. Evaluation of the 100% Condom Programme in Thailand.
71. Green EC, Halperin DT, Nantulya V, Hogle JA. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav. 2006;10:335–346. discussion 347-350. [PMC free article] [PubMed] 72. Potts M. Thinking about vaginal microbicide testing. Am J Public Health. 2000;90:188–190. [PubMed] 73. van de Wijgert J, Elias C, Ellertson C, McGrory E, Blanchard K, Friedland B, et al. Condom promotion in microbicide trials. Am J Public Health. 2000;90:1153–1154. author reply 1156. [PubMed] 74. Lurie P, Wolfe SM. Ethics require the inclusion of condoms and counseling in anti-HIV microbicide trials. Am J Public Health. 2000;90:1154–1155. author reply 1156. [PubMed] 75. de Zoysa I, Elias CJ, Bentley ME. Microbicide research and “the investigator's dilemma” Am J Public Health. 2000;90:1155. author reply 1156. [PubMed] 76. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006;6:54. [PMC free article] [PubMed] 77. Baeten JM, Richardson BA, Martin HL, Jr, Nyange PM, Lavreys L, Ngugi EN, et al. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J Acquir Immune Defic Syndr. 2000;24:458–464. [PubMed] 78. Halpern V, Obunge O, Ogunsola F, Otusanya S, Umo-Otong J, Wang CH, Mehta N. Interim data monitoring to enroll higher-risk participants in HIV prevention trials. BMC Med Res Methodol. 2009;9:44. [PMC free article] [PubMed] 79. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Keli F, MacDonald KS, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2002;30:69–72. [PubMed]
80. Centers for Disease Control and Prevention. CDC Fact Sheet. Atlanta, Georgia: Dec, 2009. Status of the Botswana TDF2 Study of Pre-Exposure Prophylaxis for HIV Prevention.
81. Merson M, Padian N, Coates TJ, Gupta GR, Bertozzi SM, Piot P, et al. Combination HIV prevention. Lancet. 2008;372:1805–1806. [PubMed] 82. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 2008;372:845–859. [PubMed] 83. Manhart LE, Holmes KK. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? J Infect Dis. 2005;191(1):S7–24. [PubMed] 84. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd. Baltimore: Williams & Wilkins; 1996. [PubMed] 85. Hill AB. The Environment and Disease: Association or Causation? Proceedings of the Royal Society of Medicine. 1965;58:295–300. [PMC free article] [PubMed]
86. Long-term Evaluation of the MEMA kwa Vijana Adolescent Sexual Health Programme in Rural Mwanza, Tanzania: a Randomised Controlled Trial. Technical Briefing Paper: No 7. 2008
87. Hargreaves JR, Bonell CP, Morison LA, Kim JC, Phetla G, Porter JD, et al. Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001-2004. AIDS. 2007;21(7):S39–48. [PubMed]